Treatment of hepatitis C
Inhibition of hepatitis B virus replication in 2.2.15 cells by expressed shRNA
Mutations in the E2–PePHD region of hepatitis C virus type 1b in patients with hepatocellular carcinoma
Characteristic sequence changes of hepatitis C virus genotype 2b associated with sustained biochemical response to IFN therapy
Lamivudine vs lamivudine and interferon combination treatment of HBeAg(−) chronic hepatitis B
Gamma-glutamyltransferase in fine-needle liver biopsies of subjects with chronic hepatitis C
Immunomodulatory effects of selective leucocytapheresis as a new adjunct to interferon-α2b plus ribavirin combination therapy
Comparison of a 6-month course peginterferon α-2b plus ribavirin and interferon α-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan
A randomized controlled trial of pegylated interferon α-2a (40 KD) or interferon α-2a plus ribavirin and amantadine vs interferon α-2a and ribavirin in treatment-naïve patients with chronic hepatitis C
The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial
Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C
Determinants of acquiring hepatitis A virus disease in a large Italian region in endemic and epidemic periods
Detection of multiple hepatitis C virus genotypes in a cohort of injecting drug users
HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma
Prevalence and sexual risk of hepatitis C virus infection when human immunodeficiency virus was acquired through sexual intercourse among patients of the Lyon University Hospitals, France, 1992–2002